Brain Tumor News

August 4, 2008 – Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme

TORONTO - July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor Center at Duke University under direction of Dr. David Reardon as Principal Investigator.
Click here to read the full press release.

July 10, 2008 – NCI Spotlights Tug McGraw Research Center on Exercise and Cancer

Five large observational studies have now linked reports of regular post-treatment physical activity with superior outcomes compared with patients who remained sedentary after treatment. And now the first prospective, randomized clinical trial is nearly set to test whether physical activity can indeed influence cancer's course after treatment.
Click here to read the full press release.